DEFERIPRONE News
DEFERIPRONE currently has 0 news articles, with 17 predicted indications.
This page combines the AI-predicted indications for DEFERIPRONE with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Evidence level: L5
- Predicted indications (17):
- hereditary persistence of fetal hemoglobin (99.0%)
- beta-thalassemia intermedia (99.0%)
- dominant beta-thalassemia (99.0%)
- beta-thalassemia and related diseases (99.0%)
- beta thalassemia (99.0%)
- hemosiderosis (99.0%)
- beta-thalassemia HBB/LCRB (99.0%)
- hemoglobinopathy (99.0%)
- hepatic porphyria (99.2%)
- early-onset familial noncirrhotic portal hypertension (99.2%)
- idiopathic copper-associated cirrhosis (99.2%)
- primitive portal vein thrombosis (99.2%)
- hepatopulmonary syndrome (99.2%)
- hepatoportal sclerosis (99.2%)
- pyruvate kinase deficiency of red cells (99.2%)
- beta-thalassemia with other manifestations (99.0%)
- pyropoikilocytosis, hereditary (99.0%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.